阿联酋在2026年1月5日首次对镰状细胞和地中海贫血进行基于CRISPR的基因治疗。 UAE administers first CRISPR-based gene therapy for sickle cell and thalassemia on Jan. 5, 2026.

2026年1月5日, 阿联酋在阿布扎比的亚斯诊所使用CARISPR-Cas9疗法CASGEVY对血红蛋白病进行了首次基因疗法治疗。 On January 5, 2026, the UAE administered its first gene-therapy treatment for hemoglobinopathies using CASGEVY, a CRISPR-Cas9 therapy, at Yas Clinic in Abu Dhabi. 该治疗获批用于12岁及以上的镰状细胞病或输血依赖β地中海贫血患者，采用精确的基因编辑技术来纠正基因突变。 The treatment, approved for patients aged 12 and older with sickle cell disease or transfusion-dependent beta thalassemia, uses precise gene editing to correct genetic mutations. 该里程碑是与阿布扎比Stem细胞中心、Vertex制药公司合作开发的,在卫生部 -- -- 阿布扎比的监督下,标志着该区域在推进尖端医疗服务方面迈出了一大步,为提供实用治疗带来了希望。 Developed in collaboration with the Abu Dhabi Stem Cells Centre, Vertex Pharmaceuticals, and under the oversight of the Department of Health–Abu Dhabi, the milestone marks a major step in advancing cutting-edge medical care in the region and offers hope for a functional cure.